Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Bromodomain inhibitors in clinical trials | Download Table
Ongoing clinical trials evaluating BET inhibitors in hematological cancers. | Download Scientific Diagram
Cancers | Free Full-Text | Role of BET Inhibitors in Triple Negative Breast Cancers | HTML
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML | Oncogene
Sierra Signs Exclusive Deal with AstraZeneca for Potent BRD4 BET Inhibitor | BioSpace
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 | Oncogenesis
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Achieving clinical success with BET inhibitors as anti-cancer agents | British Journal of Cancer
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer - ScienceDirect
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Two pathways, one destination: promising drug combination to treat ovarian cancer
Clinical trials evaluating BET inhibitors with results in patients with... | Download Scientific Diagram
Next-generation epigenetic inhibitors
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology
Small-Molecule Targeting of BET Proteins in Cancer. | Semantic Scholar
JQ1 - Wikipedia
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma - Annals of Oncology
Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs - RSC Advances (RSC Publishing) DOI:10.1039/D0RA07971E
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors | Journal of Clinical Oncology
Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma | EMBO Molecular Medicine
